Merger Updates, Milestone Payments, AGM Results, Review of Strategic Alternatives and Other Corporate Announcements - Research Report on Cubist, Halozyme, Taro, Galena and Sequenom

NEW YORK, October 1, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Galena Biopharma, Inc. (NASDAQ: GALE) and Sequenom Inc. (NASDAQ: SQNM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Cubist Pharmaceuticals Inc. Research Report

On September 13, 2013, Cubist Pharmaceuticals, Inc. (Cubist) and Optimer Pharmaceuticals, Inc. (Optimer) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR). According to Cubist, the expiration of the HSR waiting period meets one of the conditions of the previously announced merger agreement under which Cubist will acquire all of the outstanding common stock of Optimer. The Company informed that, post-closing of the merger each holder of Optimer common stock will receive $10.75 per share in cash, plus one Contingent Value Right which entitles the holder to receive an additional one-time cash payment of up to $5.00 for each share they own if certain net sales of DIFICID® (fidaxomicin) in the United States and Canada are achieved. Cubist stated that the proposed merger remains subject to approval by the stockholders of Optimer, as well as other customary closing conditions. The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-26/CBST]

Halozyme Therapeutics, Inc. Research Report

On September 26, 2013, Halozyme Therapeutics Inc. (Halozyme) announced that the commercial launch of Herceptin SC in Europe has sparked off a $10 million milestone payment to Halozyme from Roche, under the License and Collaboration Agreement between the duos. According to the Company, this time-saving subcutaneous formulation of Herceptin (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) has received marketing authorization from the European Commission on August 28, 2013 for the treatment of patients with HER2-positive breast cancer. "With pricing on par with the intravenous formulation, Herceptin SC represents a compelling treatment alternative for breast cancer patients in Europe, and we congratulate Roche on making this time-saving therapy available to patients in Europe so quickly," said Gregory I. Frost, Ph.D., President and CEO of Halozyme. "This will be the third commercial product using our rHuPH20 enzyme and represents a significant achievement for our technology and company as a whole." The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-26/HALO]

Taro Pharmaceutical Industries Ltd. Research Report  

On September 13, 2013, Taro Pharmaceutical Industries Ltd. (Taro) announced results from its annual general meeting of shareholders, held on September 12, 2013 at Euro Park, Italy House, Yakum, Israel. The Company informed that as per the voting results of its shareholders, certified and tabulated by IVS Associates, Inc, five directors (Dilip Shanghvi, Kal Sundaram, Sudhir Valia, James Kedrowski and Dov Pekelman) were re-elected to the Company's Board of Directors to serve until the close of the next annual general meeting of shareholders. Taro added that two External Directors, namely, Ilana Avidov Mor and Dan Biran, were re-elected for three-year period, commencing from December 31, 2013. Additionally, the shareholders also approved the Company's Compensation Policy in accordance with the requirements of the Israeli Companies Law, 5759-1999, besides appointing Ziv Haft, Certified Public Accountants (Israel), a BDO member firm, as the Company's independent auditors until the close of the next annual general meeting of shareholders of Taro. The Full Research Report on Taro Pharmaceutical Industries Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-26/TARO]

Galena Biopharma, Inc. Research Report

On September 23, 2013, Galena Biopharma Inc. (Galena) announced the closing of the exercise in full of the underwriters' option to purchase an additional 2.6 million shares of common stock of Galena. The Company informed that the net proceeds to Galena from the offering, including from the exercise in full of the over-allotment options, are expected to be c.$37.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Galena. The Company stated that it intends to use the proceeds for the commercialization of its first commercial product, Abstral® (fentanyl) Sublingual Tablets, and its ongoing Phase 3 NeuVax™ (nelipepimut-S) PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial and other clinical trials of its product candidates, and general corporate purposes. The Full Research Report on Galena Biopharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-26/GALE]

Sequenom Inc. Research Report

On September 23, 2013, Sequenom, Inc.'s (Sequenom) announced that its Board of Directors has approved a review of potential strategic alternatives for its Genetic Analysis business segment. The Company stated that it has retained Jefferies LLC as its financial advisor to help in the evaluation of alternatives. Sequenom informed that it does not plan to disclose or comment on developments regarding the strategic alternatives review process until further disclosure is deemed appropriate. The Full Research Report on Sequenom Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-26/SQNM]

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.InvestorsReports.com

SOURCE Investors' Reports